Burcu MESUT, Yıldız ÖZSOY, Çağla KAZAZ, Meltem OCAK

Formulation development and evaluation of taste-masked atomoxetine hydrochloride orally disintegrating tablets (ODTs)

Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor used for the treatment of attention deficit/hyperactivity disorder. Atomoxetine hydrochloride is available in the form of capsules and oral solutions, yet it has no orally disintegrating form due to its bitter taste. ODTs are formulated to disintegrate rapidly upon contact with saliva and enable oral administration without water or chewing and offer improved patient compliance and ease of administration. Appropriate taste masking has great importance for ODTs. In this study, developing a taste-masked ODT formulation containing atomoxetine hydrochloride produced using the wet granulation method was aimed. Formulations were designed by changing the granulation agent (Hydroxypropylmethylcellulose (HPMC), Gellan gum, Veegum, Polyethylene glycol (PEG) 20000P) and active substance to granulation agent ratio (1:2, 1:3, 1:4). Each formulation was tested physically and chemically. According to the results, it was concluded that Gellan gum is more appropriate for use in ODTs for taste masking.

PDF

___

[1] Nayak AK, Manna K. Current developments in orally disintegrating tablet technology. J Pharm Educ Res. 2011; 2(1): 21-34.
[2] Hirani JJ, Rathod DA, Vadalia KR. Orally Disintegrating Tablets: A Review. Trop J Pharm Res. 2009; 8(2): 161-172.
[3] Pahwa R, Piplani M, Sharma PC, Kaushik D, Nanda S. Orally Disintegrating Tablets - Friendly to Pediatrics and Geriatrics. Arch Apll Sci Res. 2010; 2(2): 35-48.
[4] Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, Flanagan T, Tuleu C. Patient-Centred Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations. Drugs. 2014; 74(16): 1871-1889.
[5] Comoglu T, Ozyilmaz ED. Orally disintegrating tablets and orally disintegrating mini tablets – novel dosage forms for pediatric use. Pharm Dev Technol. 2019; 24(7):902-914.
[6] Srivastava SK, Verma R, Chandra V, Srivastava SP. Orally disintegrating tablets; a dosage form that extends the market exclusivity and patent protection. World J Pharm Pharm Sci. 2014; 3(7): 526-546.
[7] Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015; 75: 2-9.
[8] Khan MS, Roberts MS. Challenges and innovations of drug delivery in older age. Adv Drug Deliv Rev. 2018; 135: 3- 38.
[9] Nagar P, Singh K, Chauhan I, Verma M, Yasir M, Khan A, Sharma R, Gupta N. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J Appl Pharm Sci. 2011; 01(04): 35-45.
[10] Pandey P, Dahiya M. Oral Disintegrating Tablets: A Review. Int J Pharm Res & Rev. 2016; 5(1): 50-62.
[11] Ölmez SS, Vural İ. Advantages and Quality Control of Orally Disintegrating Tablets. FABAD J Pharm Sci. 2009; 34(3): 167-172.
[12] Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, tastemasking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004; 21(6): 433-476.
[13] Walsh J, Cram A, Woertz K, Breitkreutz J, Winzenburg G, Turner R, Tuleu C. On behalf of the European Formulation Initiative (EuPFI). Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients. Adv Drug Deliv Rev. 2014; 73: 14–33.
[14] Patel Chirag J, Tyagi S, Dhruv M, Ishita M, Gupta AK, Usman MRM, Mallik J, Shree N, Paswan SK. Pharmaceutical Taste Masking Technologies Of Bitter Drugs: A Concise Review. J Drug Discov Ther. 2013; 1(5): 39-46.
[15] Gupta AK, Madaan S, Dalal M, Kumar A, Mishra DN, Singh SK, Verma S. Practical Approaches for Taste Masking of Bitter Drug: A Review. Int J Drug Deliv Technol. 2010; 2(2): 56-61.
[16] Bhalerao K, Gambhire S, Singh S. Taste Masking To Improve Compliance. Int Res J Pharm Appl Sci. 2013; 3(5): 224- 237.
[17] Abraham J, Mathew F. Taste masking of peadiatric formulation: A review on technologies, recent trends and regulatory aspects. Int J Pharm Pharm Sci. 2014; 6(1): 12-19.
[18] Sohi H, Sultana Y, Khar RK. Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches. Drug Dev Ind Pharm. 2004; 30(5): 429-448.
[19] Anand V, Kataria M, Kukkar V, Saharan V, Choudhury PK. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today. 2007; 12(5-6): 257-265.
[20] Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009; 11(3): 203-226.
[21] Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016; 26(4): 314-326.
[22] Garland M, Kirkpatrick P. Atomoxetine hydrochloride. Nat Rev Drug Discov. 2004; 3(5): 385-386.
[23] Kazaz CK. Msc Thesis. Formulation development of orally disintegrating tablet (ODT) for taste masking of drug. Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Fatih, İstanbul, Turkey, 2017.
[24] Nakano M, Witcher J, Satoi Y, Goto T. Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. Clin Drug Investig. 2016; 36(11): 903-911.
[25] Ghogari IS, Jain PS. Development of Orally Disintegrating Tablets of Memantine Hydrochloride-A Remedy For Alzheimer’s Disease. Int J App Pharm. 2020; 12(1): 147-152.
[26] Bhatti S, Kaushik M. Utilization of natural superdisintegrant in mouth dissolving tablet: A simplified review. Innov Pharm Pharmacother. 2020; 8(2): 32-38.
[27] Guideline On The Investigation Of Bioequivalence, European Medicines Agency (EMA), London 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalencerev1_en.pdf (accessed on 07 October 2017).
[28] Osmalek T, Froelich A, Tasarek S. Application of gellan gum in pharmacy and medicine. Int J Pharm. 2014; 466(1-2): 328-340.
[29] Bolourchian N, Mahboobian MM, Dadashzadeh S. The Effect of PEG Molecular Weights on Dissolution Behavior of Simvastatin in Solid Dispersions. Iran J Pharm Res. 2013; 12: 11-20.
[30] Patent US5622980A. http://www.google.com.kh/patents/US5622980 (accessed on 28 June 2017).
[31] Ito M, Ikehama K, Yoshida K, Haraguchi T, Yoshida M, Uchida T. Bitterness prediction of H1-antihistamines and prediction of masking effects of artificial sweeteners using an electronic tongue. Int J Pharm. 2013; 441(1-2): 121-127.
[32] Pauli E, Joshi H, Vasavada A, Brackett J, Towa L. Evaluation of an Immediate-Release Formulation of Hydroxychloroquine Sulfate With an Interwoven Pediatric Taste-Masking System. J Pharm Sci. 2020; 109(4): 1493- 1497.
[33] Łabańska M, Ciosek-Skibińska P, Wróblewski W. Critical Evaluation of Laboratory Potentiometric Electronic Tongues for Pharmaceutical Analysis-An Overview. Sensors (Basel). 2019; 19(24): 5376.
[34] Singh M, Dua JS, Menra M, Prasad DN. A Review On Orally Disintegrating Tablets. World J Pharm Res Technol. 2016; 4(2): 125-144.
[35] Takka S., Acartürk F., Ağabeyoğlu İ., Çelebi N., Değim T, Değim Z. Preformulation. In: Modern Pharmaceutical Technology Turkish Pharmacists’ Association. (Ed), Pharmacy Academy Literature, 2nd ed. Mattek Matbaacılık, Turkey, 2009, pp. 119-140.
[36] Atomoxetine Capsules Monograph, The United States Pharmacopeia (USP 39-NF 34), USA 2017.
[37] Maniruzzaman M, Boateng JS, Bonnefille M, Aranyos A, Mitchell JC, Douroumis D. Taste masking of paracetamol by hot-melt extrusion: an in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012; 80(2): 433–442.
[38] Wang J, Xiao H. Discrimination of different white chrysanthemum by electronic tongue. J Food Sci Technol. 2013; 50(5): 986–992
[39] Alpha MOS Northern Europe: Norlab. Application Note: Masking optimization of active principle bitterness by etongue. http://www.norlab.fi/library/application-note/10436 (accessed on 07 October 2017).
[40] Alpha MOS Northern Europe: Norlab. Application Note: Optimization of taste matching of placebos by e-tongue; http://www.norlab.fi/library/application-note/10437 (accessed on 07 October 2017).